Clinical trial
Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II Study of the EORTC-LG and GIMEMA (AML-14A Trial)
NCT00838240 is registered in ClinicalTrials.gov with European Organisation for Research and Treatment of Cancer - EORTC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II Study of the EORTC-LG and GIMEMA (AML-14A Trial)
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- November 30, 2008
- Completion date
- Not reported
- Enrollment
- 114 (estimated)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.